Important Safety Information Prescribing Information Patient Site

Office Resources

Office resources

Order YCANTH® Now

Permanent YCANTH J-code (J7354)

Effective April 1, 2024

Model is for illustrative purposes only.

Order YCANTH for your patients

Buy & Bill

FFF Enterprises, Inc

Y-Access® Support Solutions is here to help

Y-Access can assist with patient benefit investigations and automated copay enrollment for eligible patients.

1-855-YCANTHS (1-855-922-6847)

Your practice will receive a welcome call within 1 business day.

Y-AccessSupport.com
Patient Authorization Form
Patient
Authorization Form

To confirm a patient's insurance coverage

Patient Enfrollment Form
Patient
Enrollment Form

To enroll a patient in the Copay Assistance Program

Learn about the integrated benefits of the Y-Access Support Solutions Training Portal.

WATCH VIDEO

Specialty Pharmacy

Our Specialty Pharmacy Network will contact the patient to receive approval to fill the prescription, enroll your patient for copay assistance, and secure payment. Once approved, the order will ship.

Simplified prescribing process:

  • Prescriptions can be submitted through your electronic Rx (ERx): choose YCANTH in the drop-down menu
  • Prescriptions can also be submitted by phone at 1-800-315-0155 or by fax at 1-800-267-4982
    • NDC: 71349-070-01
    • Rx: YCANTH (cantharidin) topical solution, single applicator

Watch this video to see how your practice can submit prescriptions for coordinated Specialty Pharmacy fulfillment.

For additional support, please visit Nufactor.com/YCANTH

Verrica Specialty Pharmacy Network—Member Pharmacies

nufactor logo

Access, billing, and coding support

Prescribing Information

DOWNLOAD NOW

FDA Approval Letter

DOWNLOAD NOW

Pooled Phase 3 Reprint

DOWNLOAD NOW

CMS 1500 Sample

DOWNLOAD NOW

CMS 1450 Sample

DOWNLOAD NOW

Resources designed to help your practice with acquisition and reimbursement

Billing and Coding Guide

Reference this guide for proper billing and coding practices

Download

Buy & Bill Office Resource

Use this resource to access YCANTH inventory with no up-front costs

Download

Specialty Pharmacy Office Resource

Use this resource when prescribing YCANTH through our dedicated Specialty Pharmacy Network

Download

Patient savings

Copay savings for commercially insured patients*

With the YCANTH Copay Assistance Program, most of your commercially insured patients may pay as little as $25 per applicator. Eligibility requirements apply.

Enroll your patients

Most patients pay as little as:

$25

If deductible has not been met, or insurance does not cover YCANTH, patient pays practice no more than $75 per applicator.

Remind patients that flexible spending accounts (FSA) or health savings accounts (HSA) can help cover copay expenses. Healthcare expense accounts can help offset qualified out-of-pocket expenses. Encourage patients to check with their program provider. Additional terms and conditions may apply.

*
Copay Assistance Program is solely for patients' charges incurred in the use of YCANTH (cantharidin) topical solution and does not include any other related charges. For all qualified patients, Verrica is responsible for all YCANTH product costs under the Program amount and excluding the copay requirement. Your insurance provider can provide the most accurate explanation of all charges. Approval to the Program is not guaranteed. Program has an annual maximum benefit of $2,605 or 4 treatments for YCANTH, whichever occurs first. Until the patient reaches the maximum Program benefit, providing healthcare professionals may not charge the patient more than the applicable Program allowance. Patient will bear financial responsibility for all costs not covered by commercial insurance exceeding maximum benefit for YCANTH. THIS IS NOT INSURANCE. Not valid for prescriptions paid, in whole or in part, by Medicaid, Medicare, VA, DOD, TRICARE®, or other federal or state programs including any state pharmaceutical assistance programs. This Program is not valid where prohibited by law, taxed or restricted. Verrica reserves the right to rescind, revoke, terminate, or amend this offer, eligibility, and terms of use at any time without notice. Additional terms and conditions may apply.

TRICARE® is a registered trademark of the Department of Defense (DOD), DHA.

You are about to leave the YCANTHPro.com website by opening a new webpage. The site you are linking to is not controlled by Verrica Pharmaceuticals and we are not responsible for the content presented on that site.

Thank you for visiting YCANTHPro.com.

Leave site

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.

INDICATION

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.
  • Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment.
  • YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.

ADVERSE REACTIONS:

The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.

DRUG INTERACTIONS:

No studies evaluating the drug interaction potential of cantharidin have been conducted.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

OVERDOSAGE:

Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin reactions are expected and should be reported if they are severe.

DHA=Defense Health Agency; DOD=Department of Defense; NDC=National Drug Code; VA=Veterans Affairs..